As seen in Fig. 1A, lung cancer cells with driver mutations in KRAS (A549) and EGFR (H1975, H1650, PC-9), as well as cells with intrinsic resistance to chemotherapeutic agents due to mutant RAS and p53 loss (KP7B, H2009 and H1299) or acquired resistance to chemotherapy (PC9-OR and A549TR) were more sensitive to Super-EBS than to EBS. Here, KRAS is linked to lung carcinoma.